Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:29:21 EDT Tue 25 Aug 2026
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q4.62.48·2.491.32.485+0.0451.8650.91,4502,4952.46  2.51  2.4553.23  0.933515:12:52Aug 1415 min RT 2¢

Recent Trades - Last 10 of 2495
Time ETExPriceChangeVolume
15:12:52Q2.4850.045100
15:12:47Q2.480.04100
15:12:44Q2.4850.045100
15:12:34Q2.490.05100
15:12:28Q2.4850.0452,000
15:12:15Q2.4850.04540
15:12:14Q2.48890.0489214
15:12:05Q2.490.05100
15:11:56Q2.490.05100
15:11:48Q2.480.04100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-14 07:00U:FATENews ReleaseFate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
2026-08-13 08:30U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
2026-08-03 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-07-09 08:30U:FATENews ReleaseFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
2026-07-06 08:30U:FATENews ReleaseFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
2026-07-01 16:05U:FATENews ReleaseFate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
2026-06-15 08:30U:FATENews ReleaseFate Therapeutics Appoints Laura Hamill to Board of Directors
2026-06-12 08:10U:FATENews ReleaseAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
2026-06-08 09:01U:FATENews ReleaseThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
2026-06-04 08:30U:FATENews ReleaseFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
2026-06-02 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 08:30U:FATENews ReleaseFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
2026-05-21 08:30U:FATENews ReleaseFate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
2026-05-13 08:30U:FATENews ReleaseFate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
2026-05-11 08:30U:FATENews ReleaseFate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
2026-05-05 08:30U:FATENews ReleaseFate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
2026-05-04 09:00U:FATENews ReleaseFate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
2026-05-01 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-04-30 09:00U:FATENews ReleaseFate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR - East 2026 Meeting
2026-04-16 09:00U:FATENews ReleaseFate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annu